Clinical Trials Browser

Withdrawn × Trastuzumab × Clear all

NCT04419181 2025-10-14

Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

Phase 2 Withdrawn

HER2-positive Breast Cancer

NCT05356897 2024-09-19

Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05474690 2024-02-26

A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer

Phase 3 Withdrawn

Pathologic Complete Response, Breast Neoplasms

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

Phase EARLY_PHASE1 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT04512261 2022-07-01

TOPAZ

Phase 1/2 Withdrawn

Brain Neoplasms, Breast Neoplasms, Central Nervous System Diseases

NCT04464967 2021-05-12

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Phase 1/2 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Recurrence, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03846583 2020-10-23

Tucatinib + Abemaciclib + Herceptin for HER2+ MBC

Phase 1 Withdrawn

Breast Neoplasms

NCT03811418 2019-11-26

ATTILA

Phase 3 Withdrawn

Neoplasm Metastasis

NCT03766607 2019-09-19

Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer

Phase 2 Withdrawn

Gastrointestinal

Stomach Neoplasms

NCT01205217 2017-06-07

ELATE

Phase 2 Withdrawn

Breast Neoplasms

NCT02735798 2017-05-04

64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain Mets

Phase EARLY_PHASE1 Withdrawn

Brain Neoplasms

NCT00397501 2017-04-21

BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain

Phase 1/2 Withdrawn

Brain Neoplasms, Breast Neoplasms, Central Nervous System Neoplasms, Drug-Related Side Effects and Adverse Reactions

NCT00964704 2016-11-02

A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT01479179 2016-10-26

Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab

Phase 1/2 Withdrawn

Breast Neoplasms

NCT02102438 2016-08-31

Chemotherapy for Elderly Patients Diagnosed With Localized HER2 Positive Breast Cancer

Phase NA Withdrawn

Breast Neoplasms

NCT00053339 2016-07-12

Trastuzumab With or Without Tamoxifen in Treating Women With Progressive Stage IV Breast Cancer

Phase 3 Withdrawn

Breast Neoplasms

NCT01985893 2016-01-14

THOR

Phase 2 Withdrawn

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT01557764 2013-07-04

Lapatinib With Trastuzumab in Treating Patients With HER2-Negative/HER2 Mutant Metastatic Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT01137994 2013-03-13

A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT00434031 2012-07-30

CETRA

Phase 2 Withdrawn

Breast Neoplasms

NCT00054470 2012-06-29

Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms, Breast Neoplasms, Male

NCT00057993 2012-06-11

Trastuzumab and Exemestane in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms